Tandem Diabetes Stock Price, News & Analysis

Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.

News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.

Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.

This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.